WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research Dr Lana Kandalaft from the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.[audio:https://www.audiomedica.com/podcasting/oncology/130407LanaKandalaftPODCASTLoRes.mp3]
You may also like...
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer 15 Dec, 2007 For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival 28 Sep, 2009 The Disappointment of the NSABP C-08 Trial 16 Sep, 2009 Low risk prostate cancer: scope and benefits from reducing overtreatment 24 Mar, 2013
- Previous story Blood test for free tumour DNA could guide breast cancer therapy
- Next story Treating HER 2 positive metastatic breast cancer without chemotherapy?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014